Schering-Plough Provides Update on Boceprevir

[Guest guest]

http://www.therapeuticsdaily.com/news/summary.cfm?id=587864 & channelID=31

Schering-Plough Provides Update on Boceprevir Clinical Development and

Intr..PharmaLive News Archive - 23-Nov-2008The company believes boceprevir has

the potential to be a first-in-class and best-in-class protease inhibitor for

treating chronic hepatitis C. The company also announced that it is developing a

highly potent next-generation oral hepatitis C protease inhibitor that has

future best-in-class potential. In the United States, PEGINTRON is indicated for

use alone or with ribavirin for the treatment of chronic hepatitis C in patients

with compensated liver disease who have not been previously treated with

interferon alpha and who are at least 18 years of age.

Summary

•

Company reaffirms its innovation leadership and long-term commitment to

hepatitis research

•

KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough

Corporation today provided a clinical update on boceprevir, its lead

investigational oral hepatitis C protease inhibitor currently in Phase III

development.

•

The company believes boceprevir has the potential to be a first-in-class and

best-in-class protease inhibitor for treating chronic hepatitis C. The company

also announced that it is developing a highly potent next-generation oral

hepatitis C protease inhibitor that has future best-in-class potential.

•

The compound, known as SCH 900518 is currently in Phase IIa clinical

development.

•

The update was presented today as part of the company's 2008 R & D Update meeting

at its headquarters in Kenilworth, N.J.

•

" As pioneers in the hepatitis field, our vision is to apply our experience and

innovation, as we have in the past, to continue to redefine and improve

treatments for chronic hepatitis C, in the near term and in the future, " said

P. Koestler, Ph.D., executive vice president and president,

Schering-Plough Research Institute.

•

The company reported for the first time that in a Phase II study, a 48-week

boceprevir regimen achieved an unprecedented 75 percent sustained virologic

response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients

who received 4 weeks of PEGINTRON (peginterferon alfa-2b) and REBETOL®

(ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in).

•

This represents a near doubling of the 38 percent SVR 24 rate for patients in

the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2)

In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent.

[Guest guest]

http://www.therapeuticsdaily.com/news/summary.cfm?id=587864 & channelID=31

Schering-Plough Provides Update on Boceprevir Clinical Development and

Intr..PharmaLive News Archive - 23-Nov-2008The company believes boceprevir has

the potential to be a first-in-class and best-in-class protease inhibitor for

treating chronic hepatitis C. The company also announced that it is developing a

highly potent next-generation oral hepatitis C protease inhibitor that has

future best-in-class potential. In the United States, PEGINTRON is indicated for

use alone or with ribavirin for the treatment of chronic hepatitis C in patients

with compensated liver disease who have not been previously treated with

interferon alpha and who are at least 18 years of age.

Summary

•

Company reaffirms its innovation leadership and long-term commitment to

hepatitis research

•

KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough

Corporation today provided a clinical update on boceprevir, its lead

investigational oral hepatitis C protease inhibitor currently in Phase III

development.

•

The company believes boceprevir has the potential to be a first-in-class and

best-in-class protease inhibitor for treating chronic hepatitis C. The company

also announced that it is developing a highly potent next-generation oral

hepatitis C protease inhibitor that has future best-in-class potential.

•

The compound, known as SCH 900518 is currently in Phase IIa clinical

development.

•

The update was presented today as part of the company's 2008 R & D Update meeting

at its headquarters in Kenilworth, N.J.

•

" As pioneers in the hepatitis field, our vision is to apply our experience and

innovation, as we have in the past, to continue to redefine and improve

treatments for chronic hepatitis C, in the near term and in the future, " said

P. Koestler, Ph.D., executive vice president and president,

Schering-Plough Research Institute.

•

The company reported for the first time that in a Phase II study, a 48-week

boceprevir regimen achieved an unprecedented 75 percent sustained virologic

response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients

who received 4 weeks of PEGINTRON (peginterferon alfa-2b) and REBETOL®

(ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in).

•

This represents a near doubling of the 38 percent SVR 24 rate for patients in

the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2)

In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent.